Cytokinetics, Incorporated (CYTK) News

Cytokinetics, Incorporated (CYTK): $53.52

1.70 (+3.28%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add CYTK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#256 of 347

in industry

Filter CYTK News Items

CYTK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CYTK News Highlights

  • For CYTK, its 30 day story count is now at 13.
  • Over the past 21 days, the trend for CYTK's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • The most mentioned tickers in articles about CYTK are DRUG, DEC and HCM.

Latest CYTK News From Around the Web

Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study

On Thursday, Cytokinetics cleared a key performance benchmark, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an improvement to 99, an increase from 89 the day before. The clinical-stage biotech company shot up 83% on Wednesday after announcing positive results from a Phase 3 study of its experimental drug to treat heart disease. The drug, Aficamten, which treats symptomatic obstructive hypertrophic cardiomyopathy (HCM) is a contender to challenge Bristol Myer Squibb's Camzyos drug.

Yahoo | December 28, 2023

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Yahoo | December 28, 2023

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

Yahoo | December 28, 2023

Company News for Dec 28, 2023

Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA

Yahoo | December 28, 2023

Stocks Static As Post-Holiday Doldrums Hit

Stocks are struggling for direction today, as the post-holiday doldrums take full effect.

TalkMarkets.com | December 27, 2023

Why Is Cytokinetics (CYTK) Stock Up 70% Today?

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Josh Enomoto on InvestorPlace | December 27, 2023

Gold nears $2100, biotech stocks on the move: Trending tickers

Gold (GC=F) prices are inching closer to $2,100 per ounce. It's an area that has been a bit of a resistance level for the precious metal. In the world of biotech, Cytokinetics (CYTK) shares soared more than 80% after a trial for its hear drug showed promising results. Meanwhile, Iovance Biotherapeutics (IOVA) shares fell 18% after the Food and Drug Administration paused clinical trials of a lung cancer treatment following the death of a patient. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | December 27, 2023

Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug

Cytokinetics Inc. reported positive results Wednesday from a key Phase 3 study of its experimental drug to treat heart disease.

Yahoo | December 27, 2023

Cytokinetics Has Record Gain as Heart Drug Succeeds in Trial

(Bloomberg) -- Cytokinetics Inc. said its experimental drug helped patients with a genetic heart ailment in a closely watched trial.Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerApple Resumes Sale of Watches After Appeals Court Lifts US BanTesla Plans Revamp of Smash Hit Model Y From China PlantGhost Ships at Reawakened North Korea Port Put Ukraine in PerilThe drug improved exercise

Yahoo | December 27, 2023

UPDATE 1-Cytokinetics' heart disease drug meets main goal in study

Drug developer Cytokinetics said on Wednesday its experimental drug aficamten, to treat a type of chronic heart disease, had met the main goal of a keenly awaited late-stage study. Aficamten is being developed as a potential treatment for hypertrophic cardiomyopathy, which causes thickening of the heart muscles and can lead to cardiac arrest. Cytokinetics, which is banking on the success of aficamten to drive its future growth, said that the drug was well-tolerated with an adverse event profile comparable to placebo.

Yahoo | December 27, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!